GLP-1 injections recalled nationwide what to know about the affected products

An unexpected shot of bad news.A popular weight-loss shot has been recalled across the country by the FDA due to potential contamination.The US-based compounding pharmacy that issued the initial recall back in September had already been on the agency’s radar and previously received a warning.Apothecary Pharma, a compounding pharmacy based in North Carolina, is recalling 22 vials of their compounded tirzepatide, the active ingredient in Mounjaro and Zepbound, though these brand name drugs aren’t affected by the recall.Even if you didn’t buy directly from Apothecary Pharma, your medication could still be affected.The company reportedly supplies compounded tirzepatide to several telehealth providers, so check your vial’s label for the manufacturer and lot number.Recalled vials are labeled 18 mg/mL in a 4 mL multi-dose vial.Apothecary Pharma is also recalling a NAD+ injection, a popular longevity supplement, for possible contamination.Both recalls are Class II, which means that using these products could cause “temporary or medically reversible adverse health consequences” though severe health consequences are unlikely.This is not the first time the FDA has disciplined Apothecary Pharma for this reason.In December, they issued a warning letter to the company after an inspection found “serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.”The FDA regulates sterility at every stage of production — from cleanroom airflow and equipment cleaning to personnel gowning and filtration — not just through final-product testing.“Lack of assurance of sterility” means the FDA cannot guarantee the product is free of contamination because of compromised sterility at some point in the production chain.In this case, the federal agency saw operators improperly handling sterile containers, touching sterile work areas and failing to change gloves to prevent contamination, and noted visibly r...